X0306 4 2016-09-16 0 0001466301 Clovis Oncology, Inc. CLVS 0001266569 MAHAFFY PATRICK J C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY BOULDER CO 80301 1 1 0 0 President and CEO Stock Option (right to buy) 79.05 2016-09-16 4 J 0 25000 0.00 D 2025-03-02 Common Stock 25000 75000 D The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib. Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the "Remaining Shares"). The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib. /s/ Patrick J. Mahaffy 2016-09-16